Top Ten Myths About Psychedelics: Separating Fact from Fiction

- Steve Elfrink

‍

Psychedelics are gaining attention as powerful tools for mental health and self-discovery, yet misconceptions abound. These myths, often rooted in decades-old misinformation, can prevent people from understanding the potential benefits and risks of psychedelics. Below, we explore the top ten myths about psychedelics, providing a detailed, evidence-based perspective to help newcomers better understand these substances.

‍

Myth 1: Psychedelics Are Just "Party Drugs"

Fact: Psychedelics like psilocybin, LSD, and MDMA are not inherently recreational substances. While some people use them casually, their origins and therapeutic applications are far more profound. Indigenous cultures have used psilocybin mushrooms, ayahuasca, and peyote for centuries in spiritual and healing ceremonies. These substances are sacred tools for connecting with the divine and promoting communal healing.

‍

Modern clinical research, such as studies conducted at Johns Hopkins University and Imperial College London, highlights the therapeutic potential of psychedelics. For example, a 2016 Johns Hopkins study found that psilocybin-assisted therapy significantly reduced depression and anxiety in cancer patients, with effects lasting up to six months. These outcomes are far removed from the hedonistic stereotypes associated with "party drugs."

‍

Myth 2: Psychedelics Cause Brain Damage

Fact: The notion that psychedelics cause brain damage stems from early propaganda, such as the infamous "brain on drugs" campaigns. Current neuroscience tells a different story. Psychedelics are not neurotoxic, meaning they do not cause physical harm to brain cells.

‍

Brain imaging studies led by Dr. Robin Carhart-Harris have shown that psychedelics temporarily reduce activity in the brain's default mode network (DMN), a region associated with self-referential thinking and rumination. At the same time, they enhance global connectivity across the brain, allowing for increased communication between different regions, which may contribute to their therapeutic potential.

‍

Researchers have also shown that psychedelics enhance neuroplasticity—the brain's ability to adapt and reorganize itself by forming new neural connections. For example, DMT (found in ayahuasca) can increase the growth of dendritic spines, which are small protrusions on neurons involved in learning and memory. This process may facilitate cognitive and emotional flexibility, potentially supporting the brain's capacity to "rewire" itself in response to new experiences or challenges.

‍

Myth 3: Psychedelics Will Make You Go "Crazy"

Fact: The idea that psychedelics cause insanity has been debunked by decades of research. While intense psychedelic experiences can temporarily induce states of confusion or emotional distress, they very rarely lead to long-term psychiatric issues, particularly in individuals with no pre-existing mental health vulnerabilities. A recent study involving 9732 adults from the U.S. and U.K. found no increase in psychotic symptoms associated with psychedelic use, except in individuals with a personal or family history of bipolar disorder, where symptoms did increase.

‍

This highlights the importance of thorough screening for mental health conditions as part of therapeutic protocols to reduce potential risks. Additionally, some individuals may experience adverse reactions such as panic attacks, paranoia, or disorientation during a psychedelic experience. Therefore, it's crucial to approach these substances with caution and under the guidance of trained professionals.

‍

Myth 4: Psychedelics Are Addictive

Fact: Psychedelics are among the least addictive substances. They work differently from substances like cocaine, methamphetamine, or opioids, as they do not act on the brain's dopamine reward system, which plays a key role in addiction. Substances like psilocybin and LSD often result in a rapid tolerance build-up, meaning repeated use within a short period yields diminishing effects—discouraging habitual use.

‍

Moreover, psychedelics show promise in treating addiction. For example, a 2014 study found that psilocybin-assisted therapy helped people quit smoking, with an abstinence rate of 80% after six months. More recent studies suggest that psychedelics can reduce cravings for alcohol and opioids, offering hope for addiction treatment.

‍

Myth 5: You’ll Lose Control of Yourself on Psychedelics

Fact: Psychedelics alter thoughts and perceptions, but they do not make users lose control of their actions or become utterly unaware of their surroundings. Most people remain conscious and able to interact with others during a psychedelic experience. The intensity of the effects largely depends on the dose, with higher doses often producing more intense emotions, sensory effects, or visions.

‍

A critical factor in shaping a psychedelic experience is what's known as 'set and setting,' a concept popularized by psychedelic researcher Dr. Timothy Leary. 'Set' refers to the mindset of the individual taking the substance, including their expectations, mood, and mental state. 'Setting' refers to the physical and social environment in which the experience takes place.

‍

Research has shown that a calm mindset and a supportive environment significantly reduce the likelihood of panic or disorientation during a psychedelic experience. In psychedelic-assisted therapy, clinical protocols prioritize safety, such as having trained guides or therapists present to assist users in navigating challenging experiences.

‍

‍

Myth 6: Psychedelics Are "Quick Fixes" for Mental Health Issues

Fact: Psychedelics can catalyze profound psychological breakthroughs, but their effects are not automatic or guaranteed. Studies have shown that psilocybin therapy can result in lasting reductions in depression and anxiety, but these outcomes depend on proper integration. This involves reflecting on the experience, discussing it with therapists, and applying insights to daily life, a crucial step that users should be aware of and prepared for.

‍

For example, a 2020 study found that two doses of psilocybin, combined with psychotherapy, produced rapid and sustained antidepressant effects. However, participants were guided through weeks of preparatory and follow-up therapy, emphasizing that psychedelics are tools within a more extensive healing process—not standalone cures.

‍

Myth 7: All Psychedelics Are the Same

‍Fact: Psychedelics vary widely in their chemical structures, subjective effects, and therapeutic uses. While they share some commonalities, their experiences and applications differ significantly.

‍

For example, psilocybin is often associated with introspection and spiritual experiences. Many users describe them as fostering a deep connection to nature or the universe, often characterized by a sense of awe and personal insight. In contrast, LSD may be seen as more cerebral or intellectual, with some individuals finding it particularly stimulating for creativity and problem-solving. Both substances heighten sensory awareness, but LSD's effects typically last longer, up to 12 hours, compared to psilocybin’s 4-6 hours.

‍

Ayahuasca is distinctive for its visionary and purgative effects. Users often report vivid, symbolic imagery and profound insights, frequently framed as encounters with spiritual entities or journeys to alternate dimensions. The purgative effects, such as vomiting or diarrhea, are an integral part of traditional ceremonies and are viewed as a form of cleansing or release, both physically and emotionally. In its cultural context, this aspect is deemed important to the therapeutic and spiritual benefits of the experience.

‍

MDMA is considered a psychedelic by some, but it differs substantially from classic psychedelics like LSD or psilocybin. MDMA primarily enhances emotional openness, empathy, and interpersonal connection, making it particularly effective in therapeutic settings, such as treating PTSD. A 2023 phase 3 clinical trial published in Nature Medicine demonstrated that MDMA-assisted therapy significantly reduced PTSD symptoms, with 71.2% of participants no longer meeting diagnostic criteria for PTSD after treatment.

‍

Similarly, ketamine is distinct from classic psychedelics due to its dissociative effects, which can create a sense of detachment from one's body or reality. This dissociation has shown therapeutic potential, particularly in treating depression and suicidal ideation.

‍

In summary, while these substances are often grouped under the umbrella of "psychedelics," their effects, durations, and therapeutic applications can vary dramatically, providing unique tools for exploring consciousness and treating mental health conditions.

‍

Myth 8: Psychedelics Are Illegal Everywhere

Fact: The legal status of psychedelics is evolving. In 2020, Oregon became the first state to legalize psilocybin therapy, and Colorado followed in 2022. Several U.S. cities, including Denver, Oakland, and Santa Cruz, have decriminalized psychedelics.

‍

Internationally, countries like Brazil and Peru allow the use of ayahuasca in religious contexts. Psilocybin and MDMA have been reclassified in Australia, enabling authorized psychiatrists to prescribe these substances for medical use. MDMA is also on the verge of FDA approval for therapeutic use, potentially by 2026, thanks to extensive research conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS).

‍

These shifts indicate growing recognition of the therapeutic value of psychedelics. However, it's important to note that the legal status of psychedelics varies widely across different jurisdictions, and their use and possession may still be illegal in many places.

‍

Myth 9: Psychedelic Experiences Are Always Fun and Easy

Fact: Psychedelic experiences can be intense, emotionally challenging, and far from recreational for many users. While these substances often produce feelings of euphoria, awe, or insight, they can also bring unresolved emotions or deeply buried traumatic memories to the surface.

‍

This phenomenon, sometimes referred to as a "bad trip," can feel frightening or overwhelming as individuals confront fears, insecurities, or painful experiences. However, such experiences are not inherently harmful, especially when they occur in a safe, supportive environment. In fact, these challenging moments are often seen as opportunities for growth, healing, and deeper self-understanding when processed appropriately.

‍

Proper preparation, the presence of a trusted guide or sitter, and an intention to work through difficult emotions can help transform these intense experiences into valuable and meaningful insights.

‍

Myth 10: Psychedelics Have No Lasting Benefits

Fact: Psychedelics have been shown to produce long-lasting positive effects on mental health. Clinical studies demonstrate that these substances can significantly reduce symptoms of depression, anxiety, and PTSD, often with benefits lasting months or even years after treatment.

‍

For instance, MDMA-assisted therapy has shown remarkable efficacy for PTSD, with sustained improvements observed even 12 months post-treatment. Similarly, psilocybin therapy has been associated with profound and enduring reductions in depression and anxiety, often following just a few sessions. These findings highlight the potential of psychedelics to facilitate lasting emotional resilience and life satisfaction.

‍

Conclusion: The Importance of Education and Respect

Psychedelics are powerful substances with the potential to heal, but they must be approached with respect, education, and proper guidance. Dispelling myths is essential to fostering informed conversations and encouraging safe practices.

‍

As research continues to uncover the therapeutic potential of psychedelics, their role in modern medicine and personal growth becomes clearer. By understanding the facts, newcomers can approach psychedelics with the knowledge needed for safe and meaningful exploration.